- Email: [email protected]
Fe de errores de “Consejos para la mujer durante el embarazo y el puerperio”
Buitrago Ramírez F et al. Tratamiento y prevención secundaria del tromboembolismo
37. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anti coagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-7. 38. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19-25. 39. Gatt A, Van Veen JJ, Bowyer A, Woolley AM, Cooper P, Kitchen S, et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. Br J Haematol. 2008;142:946-52. 40. Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142:889-903. 41. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327-33. 42. Tripodi A, Legnani C, Palareti G, Chantarangkul V, Mannucci PM. More on: high thrombin generation and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2009;7:906-7. 43. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. Ddimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-9. 44. Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Combination of Ddimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost. 2008;6:708-10. 45. Bruinstroop E, Klok FA, Van De Ree MA, Oosterwijk FL, Huisman MV. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost. 2009;7:611-8. 46. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a rando mized trial. Ann Intern Med. 2009;150:577-85. 47. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-63.
48. Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation d-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the prolong study extension. J Thromb Haemost. 2010;8:1933-42. 49. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630-6. 50. Raskob GE, Hull RS. Low molecular weight heparin for venous thromboembolic disease. UpToDate. 2010. 51. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al, for the ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325-9. 52. Pineo GF. Prevention of venous thromboembolism disease in medical patients. UpToDate. 2010. 53. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52. 54. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. 8.ª ed. Chest. 2008;133 Suppl 6: 381S-453S. 55. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2006:CD001367. 56. Valentine KA, Hull RD. Therapeutic use of warfarin. UpToDate. 2010. 57. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8.ª ed. Chest. 2008;133:160S-198S. 58. Brull Sabaté JM, González Manero AF. Control del tratamiento anticoagulante oral en el Servicio Extremeño de Salud. Guía clínica, punción capilar y protocolos de actuación. Servicio Extremeño de Salud, 2007.
Fe de errores Fe de errores de “Consejos para la mujer durante el embarazo y el puerperio” Beatriz Arriba Marcos y Emilia Bailon Muñoz Medicina Familiar y Comunitaria. Centro de Salud Albaycín. Granada. España. En el artículo ‘‘Consejos para la mujer durante el embarazo y el puerperio” (FMC. 2010;17(6):408), se ha detectado un error en el nombre del primer autor. El nombre correcto es: Beatriz Arriba Marcos. 378 FMC. 2011;18(6):366-78
37. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, et al. A comparison of three months of anticoagulation with extended anti coagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-7. 38. Agnelli G, Prandoni P, Becattini C, Silingardi M, Taliani MR, Miccio M, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19-25. 39. Gatt A, Van Veen JJ, Bowyer A, Woolley AM, Cooper P, Kitchen S, et al. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation. Br J Haematol. 2008;142:946-52. 40. Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142:889-903. 41. Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM, et al. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost. 2008;6:1327-33. 42. Tripodi A, Legnani C, Palareti G, Chantarangkul V, Mannucci PM. More on: high thrombin generation and the risk of recurrent venous thromboembolism. J Thromb Haemost. 2009;7:906-7. 43. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. Ddimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-9. 44. Poli D, Antonucci E, Ciuti G, Abbate R, Prisco D. Combination of Ddimer, F1+2 and residual vein obstruction as predictors of VTE recurrence in patients with first VTE episode after OAT withdrawal. J Thromb Haemost. 2008;6:708-10. 45. Bruinstroop E, Klok FA, Van De Ree MA, Oosterwijk FL, Huisman MV. Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost. 2009;7:611-8. 46. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a rando mized trial. Ann Intern Med. 2009;150:577-85. 47. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S, et al. The risk of recurrent venous thromboembolism in men and women. N Engl J Med. 2004;350:2558-63.
48. Cosmi B, Legnani C, Tosetto A, Pengo V, Ghirarduzzi A, Testa S, et al. Sex, age and normal post-anticoagulation d-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the prolong study extension. J Thromb Haemost. 2010;8:1933-42. 49. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121:1630-6. 50. Raskob GE, Hull RS. Low molecular weight heparin for venous thromboembolic disease. UpToDate. 2010. 51. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al, for the ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332:325-9. 52. Pineo GF. Prevention of venous thromboembolism disease in medical patients. UpToDate. 2010. 53. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52. 54. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. 8.ª ed. Chest. 2008;133 Suppl 6: 381S-453S. 55. Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev. 2006:CD001367. 56. Valentine KA, Hull RD. Therapeutic use of warfarin. UpToDate. 2010. 57. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8.ª ed. Chest. 2008;133:160S-198S. 58. Brull Sabaté JM, González Manero AF. Control del tratamiento anticoagulante oral en el Servicio Extremeño de Salud. Guía clínica, punción capilar y protocolos de actuación. Servicio Extremeño de Salud, 2007.
Fe de errores Fe de errores de “Consejos para la mujer durante el embarazo y el puerperio” Beatriz Arriba Marcos y Emilia Bailon Muñoz Medicina Familiar y Comunitaria. Centro de Salud Albaycín. Granada. España. En el artículo ‘‘Consejos para la mujer durante el embarazo y el puerperio” (FMC. 2010;17(6):408), se ha detectado un error en el nombre del primer autor. El nombre correcto es: Beatriz Arriba Marcos. 378 FMC. 2011;18(6):366-78